These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39422764)

  • 1. Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.
    Wang D; Zhang J; Bu C; Liu G; Guo G; Zhang Z; Lv G; Sheng Z; Yan Z; Gao Y; Wang M; Liu G; Zhao R; Li T; Ma C; Bu X
    J Cancer Res Clin Oncol; 2024 Oct; 150(10):466. PubMed ID: 39422764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.
    Guo G; Zhang Z; Zhang J; Wang D; Xu S; Liu G; Gao Y; Mei J; Yan Z; Zhao R; Wang M; Li T; Bu X
    Cancer Immunol Immunother; 2024 Aug; 73(10):193. PubMed ID: 39105794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.
    Chuma M; Uojima H; Toyoda H; Hiraoka A; Arase Y; Atsukawa M; Itokawa N; Okubo T; Tada T; Numata K; Morimoto M; Sugimori M; Nozaki A; Iwasaki S; Yasuda S; Koshiyama Y; Mishima Y; Tsuruya K; Tokoro C; Miura Y; Hidaka H; Kumada T; Kusano C; Kagawa T; Maeda S
    Hepatol Int; 2024 Oct; 18(5):1472-1485. PubMed ID: 38963640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
    Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA
    Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
    Taylor K; Zou J; Magalhaes M; Oliva M; Spreafico A; Hansen AR; McDade SS; Coyle VM; Lawler M; Elimova E; Bratman SV; Siu LL
    Eur J Cancer; 2023 Jul; 188():29-38. PubMed ID: 37182343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
    Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
    Galanis E; Anderson SK; Lafky JM; Uhm JH; Giannini C; Kumar SK; Kimlinger TK; Northfelt DW; Flynn PJ; Jaeckle KA; Kaufmann TJ; Buckner JC
    Clin Cancer Res; 2013 Sep; 19(17):4816-23. PubMed ID: 23833308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer.
    Jiang R; Cheng X; Li P; Meng E; Wu X; Wu H
    Sci Rep; 2024 Jun; 14(1):14027. PubMed ID: 38890392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
    Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
    JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
    Cuppini L; Calleri A; Bruzzone MG; Prodi E; Anghileri E; Pellegatta S; Mancuso P; Porrati P; Di Stefano AL; Ceroni M; Bertolini F; Finocchiaro G; Eoli M
    PLoS One; 2013; 8(9):e74345. PubMed ID: 24069296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
    Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
    J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
    Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
    Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
    Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
    Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
    Nayak L; Standifer N; Dietrich J; Clarke JL; Dunn GP; Lim M; Cloughesy T; Gan HK; Flagg E; George E; Gaffey S; Hayden J; Holcroft C; Wen PY; Macri M; Park AJ; Ricciardi T; Ryan A; Schwarzenberger P; Venhaus R; Reyes ML; Durham NM; Creasy T; Huang RY; Kaley T; Reardon DA
    Clin Cancer Res; 2022 Jun; 28(12):2567-2578. PubMed ID: 35395080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
    Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
    J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
    Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
    Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.
    Tabouret E; Boudouresque F; Barrie M; Matta M; Boucard C; Loundou A; Carpentier A; Sanson M; Metellus P; Figarella-Branger D; Ouafik L; Chinot O
    Neuro Oncol; 2014 Mar; 16(3):392-9. PubMed ID: 24327581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.